2026-06-02T08:14:42Zhttps://riuma.uma.es/rest/oai/request

oai:riuma.uma.es:10630/339182026-02-03T10:56:45Zcom_10630_2254col_10630_37953

Oliver-Martos, Begoña Órpez, Teresa Pinto-Medel, Maria Jesús Mayorga Mayorga, Cristobalina García-León, Juan Antonio Maldonado-Sanchez, Rafael Suardíaz García, Margarita Guerrero, Miguel Luque, Gloria Leyva-Fernández, Laura Fernández Fernández, Óscar 2024-09-29T10:07:01Z 2024-09-29T10:07:01Z 2011 Oliver-Martos B, Órpez T, Pinto-Medel MJ, Mayorga C, García-León JA, Maldonado-Sanchez R, Suardíaz M, Guerrero M, Luque G, Leyva L, Fernández O. Gene expression in IFNß signalling pathway differs between monocytes, CD4 and CD8 T cells from MS patients. J Neuroimmunol. 2011 Jan;230(1-2):153-9. doi: 10.1016/j.jneuroim.2010.10.033. Epub 2010 Nov 24. PMID: 21106255. https://hdl.handle.net/10630/33918 10.1016/j.jneuroim.2010.10.033 IFNß exerts its activity through the interaction with IFNAR, through activation of the JAK/STAT pathway. We analyzed the changes in IFNAR1, IFNAR2, STAT1, STAT2, Tyk2, JAK1, IRF9 and MxA gene expressions after prolonged IFNß treatment, in isolated mononuclear-cell subpopulations from MS patients, by real time PCR. The effect of IFNß on gene expression differed depending on the subpopulation assessed. The data suggest that CD8+ T cells are the most influenced by prolonged IFNß therapy as IFNAR2, Tyk2, IRF9 and Jak1 expressions were decreased, whereas MxA expression was increased in these cells. eng open access Esclerosis múltiple Gene expression in IFNß signalling pathway differs between monocytes, CD4 and CD8 T cells from MS patients journal article